# A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

> **NCT02110355** · PHASE1 · COMPLETED · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Advanced Malignancy
- Advanced Solid Tumors
- Cancer
- Oncology
- Oncology Patients
- Tumors
- Melanoma

## Interventions

- **DRUG:** AMG 232
- **DRUG:** Trametinib
- **DRUG:** Dabrafenib

## Key facts

- **NCT ID:** NCT02110355
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-19
- **Primary completion:** 2018-12-27
- **Final completion:** 2018-12-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110355, "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02110355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*